Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer
Status:
Completed
Trial end date:
2015-02-13
Target enrollment:
Participant gender:
Summary
RATIONALE: Ridaforolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying the side effects of ridaforolimus and to see how
well it works in treating patients with recurrent metastatic and/or locally advanced
endometrial cancer.